Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.12
+0.10 (1.99%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Immuneering Employees
Immuneering had 53 employees as of December 31, 2025. The number of employees decreased by 13 or -19.70% compared to the previous year.
Employees
53
Change
-13
Growth
-19.70%
Revenue / Employee
n/a
Profits / Employee
-$1,057,074
Market Cap
331.02M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 53 | -1 | -1.85% |
| Sep 30, 2025 | 54 | -12 | -18.18% |
| Jun 30, 2025 | 54 | -12 | -18.18% |
| Mar 31, 2025 | 54 | -11 | -16.92% |
| Sep 30, 2024 | 66 | -1 | -1.49% |
| Jun 30, 2024 | 66 | 0 | - |
| Mar 31, 2024 | 65 | -3 | -4.41% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Sep 30, 2023 | 67 | -7 | -9.46% |
| Jun 30, 2023 | 66 | -8 | -10.81% |
| Mar 31, 2023 | 68 | 0 | - |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Sep 30, 2022 | 74 | 38 | 105.56% |
| Jun 30, 2022 | 74 | 40 | 117.65% |
| Mar 31, 2022 | 68 | 36 | 112.50% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Sep 30, 2021 | 36 | 10 | 38.46% |
| Jun 30, 2021 | 34 | - | - |
| Mar 31, 2021 | 32 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| Armata Pharmaceuticals | 60 |
| PepGen | 56 |
| Ovid Therapeutics | 23 |
| Immix Biopharma | 21 |
| Opus Genetics | 18 |
| XOMA Royalty | 14 |
| Minerva Neurosciences | 8 |
IMRX News
- 6 days ago - Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival - GlobeNewsWire
- 17 days ago - Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 21 days ago - Immuneering to Present at the Leerink Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data - Seeking Alpha
- 2 months ago - Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower - Benzinga
- 2 months ago - Immuneering Corporation (IMRX) Discusses Positive 12-Month Overall Survival Update From Phase IIa Trial of Atebimetinib in First-Line Pancreatic Cancer Transcript - Seeking Alpha
- 2 months ago - Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - GlobeNewsWire